Lilly and Novo Seek an Amylin Path Beyond GLP-1 Drugs

Eli Lilly and Novo are developing amylin drugs as another biological approach to treating obesity and diabetes beyond GLP-1 therapies.

Eli Lilly and Novo are developing amylin drugs to pursue another biological route for treating obesity and diabetes. The significance is not that GLP-1 therapies are being replaced, but that the companies are exploring whether a different target can broaden what treatment delivers.

For investors, that creates a distinction between an attractive scientific idea and a valuable medicine. A new biological approach offers a reason to conduct research. It does not, by itself, establish better outcomes, a tolerable treatment or a commercially viable product.

The development efforts were reported by CNBC. The available facts establish that both companies are working on amylin drugs for obesity and diabetes, but do not provide program-specific trial results, development stages or approval schedules. That limits how precisely their prospects can be compared.

A different target, not a proven replacement

Amylin and GLP-1 represent different biological approaches. The central proposition behind the new programs is that treating obesity and diabetes need not depend on the same biological lever. Exploring another target could give drug developers additional ways to address those conditions.

That distinction matters, but it should not be stretched into a claim of superiority. A drug can act through a different pathway without producing a better result for patients. Whether the difference is useful depends on evidence collected in people, not simply on how distinct the underlying idea sounds.

The phrase “after GLP-1s” is therefore best understood as a development direction rather than a forecast that one class will displace another. Amylin drugs could eventually have a separate role, a complementary role or a more limited role. The supplied information does not establish which outcome is most likely.

Nor does it establish how Lilly’s and Novo’s individual programs differ. Without details about the candidates, study designs and results, there is no sound basis here for declaring a leader. A shared target does not mean identical medicines, but it also does not reveal a competitive advantage.

The evidence that would establish a useful medicine

The next meaningful question is what benefits an amylin drug can demonstrate and under what conditions. For obesity, evidence would need to show the treatment’s effect on weight alongside its safety and tolerability. For diabetes, evidence would need to establish its effect on blood-sugar management and the broader balance of benefits and risks.

These are evaluation questions, not reported findings about either company’s candidates. No numerical clinical outcomes are supplied. Assigning an expected weight-loss result or claiming better diabetes control would go beyond the available evidence.

Comparisons also require care. Results from separate studies can reflect differences in the people enrolled, the treatment period, the dose or the way outcomes are measured. A favorable result in one setting would not automatically prove that a candidate is better than a GLP-1 treatment studied under different conditions.

Tolerability—the extent to which patients can comfortably remain on treatment—would be important alongside effectiveness. A medicine that produces an encouraging result but is difficult to continue could have a different practical value from one that patients can use consistently. That is a general clinical consideration, not an assertion about side effects in these programs.

For patients, the relevant promise is another potential option. Development activity alone does not establish that such an option is available, appropriate for a particular person or close to approval.

Pipeline ambition meets a cautious market snapshot

The market data showed both companies’ shares lower even as broad-market trackers advanced. At the last-trade timestamp of October 2, 2026, at 16:31:44 GMT, Lilly’s LLY quote was down 0.76% on the day and Novo’s NVO quote was down 0.45%. These were live intraday readings, not closing results.

The same snapshot showed a 0.69% gain for the S&P 500 tracker and a 1.05% gain for the Nasdaq 100 tracker. The contrast provides market context, but it does not establish that the amylin development story caused either company’s decline.

A share-price move captures trading at a particular moment. It cannot establish the quality of a drug candidate, explain every investor’s reasoning or substitute for clinical evidence. There is no supplied basis for attributing these moves specifically to enthusiasm or concern about amylin.

The commercial question is longer-term: could a successful candidate give either company a differentiated treatment? That possibility would depend first on demonstrated medical value. It would then require decisions about positioning, access and use that cannot be resolved from the development announcement.

A broader pipeline can create additional opportunities, but development also carries uncertainty. Investors should distinguish the existence of a program from evidence that it will become an approved product, and distinguish approval from evidence of commercial success.

What would make the next update consequential

A useful future update would connect the biological rationale to an identifiable clinical result. Details about who was studied, what treatment was tested, how outcomes were measured and what safety findings emerged would allow a more concrete assessment than the target alone.

Program-specific information would also make the Lilly-Novo comparison more meaningful. Until those details are available, ranking the companies on amylin would confuse a shared strategic direction with demonstrated execution.

The important development is that both companies are pursuing another route into obesity and diabetes treatment. The investment case remains conditional: amylin’s value will rest on what the medicines demonstrate, not on the novelty of the target or the promise implied by a new wave of drugs.

Key facts

• Development focus: Eli Lilly and Novo are developing amylin drugs for obesity and diabetes.
• Lilly market snapshot: LLY: 1141.15, down 0.76%; currency and exchange not supplied. Last trade: October 2, 2026, 16:31:44 GMT.
• Novo market snapshot: NVO: 37.23, down 0.45%; currency and exchange not supplied. Last trade: October 2, 2026, 16:31:44 GMT.
• Evidence boundary: The supplied facts do not include candidate names, clinical results, development stages or approval schedules.

Frequently asked questions

What are Lilly and Novo developing?

Eli Lilly and Novo are developing amylin drugs for obesity and diabetes. The programs pursue another biological approach beyond GLP-1 therapies. The available information establishes that development is underway, but does not identify individual candidates, trial stages, numerical clinical results or expected approval dates.

How do amylin programs differ from GLP-1 therapies?

The supplied facts describe amylin as another biological lever for treating obesity and diabetes, distinct from the GLP-1 approach. That difference provides a scientific rationale for development, but does not establish superior effectiveness or safety. Program-specific evidence would be needed to explain how each candidate performs in patients.

Will amylin drugs replace GLP-1 treatments?

The available evidence does not establish that amylin drugs will replace GLP-1 treatments. A different biological target could support a separate or complementary treatment role, but that remains a possibility rather than a demonstrated outcome. Clinical findings and subsequent regulatory decisions would be necessary to define their role.

Which company has the stronger amylin program?

There is not enough program-specific information in the supplied facts to rank Lilly against Novo. Both are developing amylin drugs, but no candidate-level results or development stages are provided. A credible comparison would require evidence about effectiveness, safety, study design and the patients included in each program.

How were Lilly and Novo shares trading?

At the October 2, 2026, last-trade timestamp of 16:31:44 GMT, LLY was down 0.76% and NVO was down 0.45% on the day. These were live intraday readings, not closing prices. The supplied data do not establish that the amylin story caused either decline.

What should investors watch for next?

Investors should look for program-specific clinical evidence showing benefits, safety and tolerability, along with details that make comparisons meaningful. Development stages and regulatory updates would help clarify the path forward. A distinct biological target is a starting point for research, not proof of an approved or commercially successful medicine.

Sources

• Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s — CNBC Top News

Photo: Belova59 · Pixabay Content License — source